FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to 3α-ethynyl, 3β-hydroxy, 5α-prignan-20-oxime or its pharmaceutically acceptable salt. Invention also relates to pharmaceutical composition.
EFFECT: technical result: obtaining new compound 3α-ethynyl, 3β-hydroxy, 5α-prignan-20-oxime, which can act as an antagonist to GABA-receptor.
2 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW STEROID COMPOUNDS SHOWING HIGHER WATER SOLUBILITY AND METABOLISM RESISTANCE, AND METHODS FOR PREPARING THEM | 2007 |
|
RU2458065C2 |
| STEROID COMPOUND FOR USE IN TREATMENT OF HEPATIC ENCEPHALOPATHY | 2015 |
|
RU2684616C2 |
| STEROID COMPOUNDS (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF PATIENTS WITH NERVOUS DISORDERS (VARIANTS) AND METHOD OF ANESTHESIA INDUCTION IN ANIMAL | 1995 |
|
RU2176248C2 |
| NEUROACTIVE STEROIDS, PHARMACEUTICAL PREPARATION, METHOD OF TREATMENT AND PROPHYLAXIS OF DIFFERENT DISORDERS, METHOD OF SLEEP INDUCTION AND METHOD OF ANESTHESIA INDUCTION WITH THEIR USING, METHOD OF MODULATION OF COMPLEX RECEPTOR GABAA-CHLORIDE IONOPHORE | 1996 |
|
RU2194712C2 |
| PHARMACEUTICAL COMPOSITION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME | 2018 |
|
RU2779262C2 |
| NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS AND METHODS OF TREATMENT USING SAME | 2013 |
|
RU2663665C2 |
| ORGANIC COMPOUNDS | 2019 |
|
RU2809023C2 |
| GABA-STEROID ANTAGONISTS AND APPLICATION THEREOF IN TREATING CNS DISTURBANCES | 2005 |
|
RU2413516C2 |
| CB1 RECEPTOR ANTAGONISTS | 2012 |
|
RU2593751C2 |
| DERIVATIVES OF PREGNENOLONE | 2013 |
|
RU2667065C2 |
